High FLT3 expression is linked to improved OS in HCC patients treated with sorafenib, although HCC patients with high FLT3 expression or increased copy numbers have a worse prognosis (Cerami et al., 2012; Lai et al., 2022a). The gene discussed is FLT3; the disease is hepatocellular carcinoma.